InMed Pharmaceuticals Inc.
INM
1.29 $
1 Tag: N/A
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer INM
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Aktuelle News
-
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
Vorschau anzeigen
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.As previously disclosed, the Company was notified by Nasdaq
-
INM Stock Alert: What to Know as InMed, Mentari Announce Merger
Vorschau anzeigen
InMed stock rallied yesterday on a merger announcement with Mentari Therapeutics. Here’s why the transaction is concerning for INM investors.
-
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)
Vorschau anzeigen
The merger shifts InMed toward migraine prevention therapies while a large private financing is expected to fund operations through key clinical milestones. Key Investor TakeawaysInMed Pharmaceuticals (NASDAQ:INM) announced an all-stock merger with private biotech company Mentari Therapeutics focused on migraine prevention therapies.
-
A migraine drugmaker heads to the public markets through reverse merger
Vorschau anzeigen
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.
-
InMed Pharmaceuticals Amends Preferred Investment Options
Vorschau anzeigen
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreement with Armistice Capital Master Fund Ltd. ("Armistice") in respect of certain outstanding preferred investment options held by Armistice.As previously...